Preventing Aggregation of Recombinant Interferon beta-1b in Solution by Additives: Approach to an Albumin-Free Formulation

Najmeh Mahjoubi ¹, Mohammad Reza Fazeli ¹ * , Rassoul Dinarvand ², Mohammad Reza Khoshayand ¹, Ahmad Fazeli ³ * , Mohammad Taghavian ¹, Hossein Rastegar ⁴

Cited by CrossRef: 5

1- Hernández-Longoria R, Hernández-Ruiz Y, Gutiérrez-Jasso F, Zarazúa A. Validation of an analytical method for the quantification of human fibrinogen in pharmaceutical products by size-exclusion liquid chromatography (SEC-HPLC). Int J Hematol. 2021;113(4):480 [Crossref]

2- Mary A, Hénaut L, Macq P, Badoux L, Cappe A, Porée T, Eckes M, Dupont H, Brazier M. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience. Front Pharmacol. 2020;11 [Crossref]

3- Mohd Nordin U, Ahmad N, Salim N, Tajuddin H, Abu Bakar N, Narasimhan A. Performance of alkyl β-D-maltosides in molecular self-assembly and formation of oil-in-water nanoemulsions as drug delivery systems. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2023;674:131886 [Crossref]

4- Imani M, Shahmohamadnejad S. Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose. 3 Biotech. 2017;7(3) [Crossref]